<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: <z:hpo ids='HP_0001081'>Gallstones</z:hpo> are a frequent complication of <z:hpo ids='HP_0001878'>hemolytic anemias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The association with the mutation of the A(TA)nTAA motif of the promoter of the <z:chebi fb="0" ids="16990">bilirubin</z:chebi> <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase gene has also been reported to increase the risk of <z:hpo ids='HP_0001081'>gallstones</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the prevalence of <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo> in <z:e sem="disease" ids="C0085578,C0472766" disease_type="Disease or Syndrome" abbrv="">thalassemia minor</z:e> and the role of the Gilbert mutation </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN AND METHODS: A group of 143 women obligate carriers of <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e>, and a control group of 170 hematologically <z:mpath ids='MPATH_458'>normal</z:mpath> women were compared </plain></SENT>
<SENT sid="4" pm="."><plain>In both groups serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi>, total cholesterol, and alanine-aminotransferase were measured and analysis of the mutation of the UGT-1A gene was performed </plain></SENT>
<SENT sid="5" pm="."><plain>On the same occasion the women underwent ultrasonography </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Total and unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> were significantly higher in <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e> heterozygotes </plain></SENT>
<SENT sid="7" pm="."><plain>Carriers of <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> had a higher prevalence of <z:hpo ids='HP_0001081'>gallstones</z:hpo> (20.3% vs 10.6% OR=2.15) </plain></SENT>
<SENT sid="8" pm="."><plain>Among the control group, the prevalence of <z:hpo ids='HP_0001081'>gallstones</z:hpo> did not differ significantly in relation to UGT1-A1 genotype, while in women carriers of <z:e sem="disease" ids="C0005283" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia</z:e> it increased in an allele dose-dependent fashion </plain></SENT>
<SENT sid="9" pm="."><plain>As compared to the controls, the odds ratios for the development of <z:hpo ids='HP_0001081'>gallstones</z:hpo> in thalassemic women were 1.68 (95% C.I.: 0.70-4.03) for those who had the <z:mpath ids='MPATH_458'>normal</z:mpath> UGT1-A1 genotype [(TA)6/(TA)6], 2.31 (95% C.I.: 1.06-5.02) for heterozygote carriers of the mutated genotype [(TA)7/(TA)6] and 3.88 (95% C.I.: 1.31-11.55) for those homozygous for the mutated genotype [(TA)7/(TA)7] </plain></SENT>
<SENT sid="10" pm="."><plain>INTERPRETATION AND CONCLUSIONS: <z:e sem="disease" ids="C0085578,C0472766" disease_type="Disease or Syndrome" abbrv="">Thalassemia minor</z:e> represents a risk factor for <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo> and the Gilbert mutation further increases this risk </plain></SENT>
<SENT sid="11" pm="."><plain>This is an additional example of how two genotypes can interact and modify a phenotype </plain></SENT>
</text></document>